An association study between heme oxygenase-1 genetic variants and Parkinson’s disease

Frontiers in Cellular Neuroscience

Volumn 8, Issue SEP, 2014, Pages 1-8

  Ayuso, Pedro ^a,b   Martínez, Carmen ^a,b   Pastor, Pau ^b,c,d   Lorenzo Betancor, Oswaldo ^c,d   Luengo, Antonio ^a   Jiménez Jiménez, Félix J ^e   Alonso Navarro, Hortensia ^e   Agúndez, José A G ^a,b   García Martín, Elena ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

Biomarkers; Blood brain barrier; Copy number variations; Heme oxygenase; Iron homeostasis; Parkinson s disease; Polymorphisms

Indexed keywords

BILIVERDIN; CARBON MONOXIDE; FERROUS ION; HEME; HEME OXYGENASE 1; IRON; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DNA STRUCTURE; FEMALE; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HMOX1 GENE; HUMAN; MALE; MEMBRANE PERMEABILITY; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 84907578838     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00298     Document Type: Article

References (54)

1. Agundez, J. A., Golka, K., Martinez, C., Selinski, S., Blaszkewicz, M., and Garcia-Martin, E. (2008b). Unraveling ambiguous NAT2 genotyping data. Clin. Chem. 54, 1390–1394. doi: 10.1373/clinchem.2008.105569
2. Agundez, J. A., Jimenez-Jimenez, F. J., Alonso-Navarro, H., and Garcia-Martin, E. (2013). Genetic biomarkers of essential tremor: time to think outside of the box. Pharmacogenomics 14, 1681–1682. doi: 10.2217/pgs.13.168
3. Agundez, J. A., Luengo, A., Herraez, O., Martinez, C., Alonso-Navarro, H., Jimenez-Jimenez, F. J., et al. (2008a). Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson’s disease. Neuromolecular Med. 10, 10–16. doi: 10.1007/s12017-007-8017-7
4. Alonso-Navarro, H., Jimenez-Jimenez, F. J., Garcia-Martin, E., and Agundez, J. A. (2014). Genomic and pharmacogenomic biomarkers of Parkinson’s disease. Curr. Drug Metab. 15, 129–181. doi: 10.2174/138920021502140327175404
5. Alonso-Navarro, H., Jiménez-Jiménez, F. J., Pilo-de-la-Fuente, B., and Plaza-Nieto, J. F. (2008). “Mecanismos patogénicos de la enfermedad de Parkinson,” in Tratado de los Trastornos del Movimiento, eds F. J. Jiménez-Jiménez, M. R. Luquin, J. A. Molina, and G. Linazasoro (Barcelona: Viguera Editores), 425–485.
6. Ayuso, P., Martinez, C., Lorenzo-Betancor, O., Pastor, P., Luengo, A., Jimenez-Jimenez, F. J., et al. (2011). A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson’s disease. Pharmacogenet. Genomics 21, 565–571. doi: 10.1097/FPC.0b013e328348f729
7. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1, 289–300.
8. Berg, D., and Hochstrasser, H. (2006). Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21, 1299–1310. doi: 10.1002/mds.21020
9. Castellani, R., Smith, M. A., Richey, P. L., and Perry, G. (1996). Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 737, 195–200. doi: 10.1016/0006-8993(96)00729-9
10. Delic, J., Onclercq, R., and Moisan-Coppey, M. (1991). Inhibition and enhancement of eukaryotic gene expression by potential non-B DNA sequences. Biochem. Biophys. Res. Commun. 181, 818-826. doi: 10.1016/0006-291X(91)91263-C
11. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, R, Agid, Y., Lees, A., et al. (1989). Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J. Neurochem. 52, 381-389. doi: 10.1111/j.1471-4159.1989.tb09133.x
12. Dore, S., Takahashi, M., Ferris, C. D., Zakhary, R., Hester, L. D., Guastella, D., et al. (1999). Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U.S.A. 96, 2445-2450. doi: 10.1073/pnas.96.5.2445
13. Droge, W. (2002). Free radicals in the physiological control of cell function. Physiol Rev. 82,47-95. doi: 10.1152/physrev.00018.2001
14. Faucheux, B. A., Bonnet, A. M., Agid, Y., and Hirsch, E. C. (1999). Blood vessels change in the mesencephalon of patients with Parkinson’s disease. Lancet 353, 981-982. doi: 10.1016/S0140-6736(99)00641-8
15. Funke, C, Tomiuk, J., Riess, O., Berg, D., and Soehn, A. S. (2009). Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson’s disease patients.J. Neural Transm. 116, 853-859. doi: 10.1007/s00702-009-0237-6
16. Garcia-Martin, E., Ayuso, P., Luengo, A., Martinez, C., and Agundez, J. A. (2008). Genetic variability of histamine receptors in patients with Parkinson’s disease. BMC Med. Genet. 9:15. doi: 10.1186/1471-2350-9-15
17. Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., et al. (2004). Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63, 1912-1917. doi: 10.1212/01.WNL.0000144276.29988.C3
18. Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55, 181-184. doi: 10.1136/jnnp. 55.3.181
19. Infante, J., Garcia-Gorostiaga, I., Sanchez-Juan, P., Sierra, M., Martin-Gurpegui, J. L., Terrazas, J., et al. (2010). Synergistic effect of two oxidative stress-related genes (heme oxygenase-1 and GSK3beta) on the risk of Parkinson’s disease. Eur. J. Neurol. 17, 760-762. doi: 10.1111/j.1468-1331.2009.02908.x
20. Jimenez-Jimenez, F. J., Alonso-Navarro, H., Garcia-Martin, E., and Agundez, J. A. (2014). COMT gene and risk for Parkinson’s disease: a systematic review and meta-analysis. Pharmacogenet. Genomics 24, 331-339. doi: 10.1097/FPC.0000000000000056
21. Kim, S. Y, Buckwalter, M., Soreq, H., Vezzani, A., and Kaufer, D. (2012). Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia 53(Suppl. 6), 37-44. doi: 10.1111/j.1528-1167.2012.03701.x
22. Kimpara, T., Takeda, A., Watanabe, K., Itoyama, Y, Ikawa, S., Watanabe, M., et al. (1997). Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum. Genet. 100, 145-147. doi: 10.1007/s004390050480
23. Kinobe, R. T., Vlahakis, J. Z., Vreman, H. J., Stevenson, D. K., Brien, J. E, Szarek, W. A., et al. (2006). Selectivity of imidazole-dioxolane compounds for in vitro inhibition of microsomal haem oxygenase isoforms. Br. J. Pharmacol. 147, 307-315. doi: 10.1038/sj.bjp.0706555
24. Kramer, M., Sponholz, C., Slaba, M., Wissuwa, B., Claus, R. A., Menzel, U., et al. (2013). Alternative 5' untranslated regions are involved in expression regulation of human heme oxygenase-1. PLoS ONE 8:e77224. doi: 10.1371/jour-nal.pone.0077224
25. Loboda, A., Jazwa, A., Grochot-Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., et al. (2008). Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 10, 1767-1812. doi: 10.1089/ars.2008.2043
26. Lorenzo-Betancor, O., Samaranch, L., Garcia-Martin, E., Cervantes, S., Agundez, J. A., Jimenez-Jimenez, F. J., et al. (2011). LINGO1 gene analysis in Parkinson’s disease phenotypes. Mov Disord. 26, 722-727. doi: 10.1002/mds.23452
27. Lu’o’ng, K., and Nguyen, L. T. (2012). Thiamine and Parkinson’s disease. J. Neurol. Sci. 316, 1-8. doi: 10.1016/j.jns.2012.02.008
28. Maines, M. D. (1997). The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37, 517-554. doi: 10.1146/annurev.pharmtox.37.1.517
29. Naylor, L. H., and Clark, E. M. (1990). d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription. Nucleic Acids Res. 18, 1595-1601. doi: 10.1093/nar/18.6.1595
30. Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., et al. (2010). Missing pieces in the Parkinson’s disease puzzle. Nat. Med. 16, 653–661. doi: 10.1038/nm.2165
31. Ono, K., Goto, Y., Takagi, S., Baba, S., Tago, N., Nonogi, H., et al. (2004). A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 173, 315–319. doi: 10.1016/j.atherosclerosis.2003.11.021
32. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575. doi: 10.1086/519795
33. Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., and Rajput, A. (2009). Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73, 206–212. doi: 10.1212/WNL.0b013e3181ae7af1
34. Rieder, C. R., Williams, A. C., and Ramsden, D. B. (2004). Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells. Braz. J. Med. Biol. Res. 37, 1055–1062. doi: 10.1590/S0100-879X2004000700015
35. Ryter, S. W., and Tyrrell, R. M. (2000). The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radic. Biol. Med. 28, 289–309. doi: 10.1016/S0891-5849(99)00223-3
36. Scapagnini, G., D’Agata, V., Calabrese, V., Pascale, A., Colombrita, C., Alkon, D., et al. (2002). Gene expression profiles of heme oxygenase isoforms in the rat brain. Brain Res. 954, 51–59. doi: 10.1016/S0006-8993(02)03338-3
37. Schapira, A. H. (2012). Mitochondrial diseases. Lancet 379, 1825–1834. doi: 10.1016/S0140-6736(11)61305-6
38. Schapira, A. H. (2013). Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 26, 395–400. doi: 10.1097/WCO.0b013e3283633741
39. Schipper, H. M. (1998). Experimental induction of corpora amylacea in adult rat brain. Microsc. Res. Tech. 43, 43–48.
40. Schipper, H. M. (2004). Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res. Rev. 3, 265–301. doi: 10.1016/j.arr.2004.02.001
41. Schipper, H. M., Song, W., Zukor, H., Hascalovici, J. R., and Zeligman, D. (2009). Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J. Neurochem. 110, 469–485. doi: 10.1111/j.1471-4159.2009.06160.x
42. Schrag, A., and Schott, J. M. (2006). Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 5, 355–363. doi: 10.1016/S1474-4422(06)70411-2
43. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., et al. (1988). Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199–205. doi: 10.1007/BF01244786
44. Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989. doi: 10.1086/319501
45. Tanaka, G., Aminuddin, F., Akhabir, L., He, J. Q., Shumansky, K., Connett, J. E., et al. (2011). Effect of heme oxygenase-1 polymorphisms on lung function and gene expression. BMC Med. Genet. 12:117. doi: 10.1186/1471-2350-12-117
46. Tiroch, K., Koch, W., von Beckerath, N., Kastrati, A., and Schomig, A. (2007). Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur. Heart J. 28, 968–973. doi: 10.1093/eurheartj/ ehm036
47. Trinh, J., and Farrer, M. (2013). Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 9, 445–454. doi: 10.1038/nrneurol.2013.132
48. Verma, A., Hirsch, D. J., Glatt, C. E., Ronnett, G. V., and Snyder, S. H. (1993). Carbon monoxide: a putative neural messenger. Science 259, 381–384. doi: 10.1126/science.7678352
49. Weinreb, O., Mandel, S., Youdim, M. B., and Amit, T. (2013). Targeting dysregu-lation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radic. Biol. Med. 62, 52–64. doi: 10.1016/j.freeradbiomed.2013.01.017
50. Whitton, P. S. (2007). Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br. J. Pharmacol. 150, 963–976. doi: 10.1038/sj.bjp. 0707167
51. Yamada, N., Yamaya, M., Okinaga, S., Nakayama, K., Sekizawa, K., Shibahara, S., et al. (2000). Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet. 66, 187–195. doi: 10.1086/302729
52. Youdim, M. B. (2003). Rasagiline: an anti-Parkinson drug with neuroprotective activity. Expert Rev. Neurother. 3, 737–749. doi: 10.1586/14737175.3.6.737
53. Zeevalk, G. D., Razmpour, R., and Bernard, L. P. (2008). Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed. Pharmacother. 62, 236–249. doi: 10.1016/j.biopha.2008.01.017
54. Zhou, C., Huang, Y., and Przedborski, S. (2008). Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann. N.Y. Acad. Sci. 1147, 93–104. doi: 10.1196/annals.1427.023